title: Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
abstract: Normalization of fluorodeoxyglucose positron emission tomography (FDG PET) imaging prior to high-dose therapy and autologous stem cell transplantation (ASCT) improves outcomes in relapsed and refractory (RR) Hodgkin lymphoma (HL), but many patients refractory to platinum-based salvage regimens are unable to achieve this goal. We therefore investigated whether brentuximab vedotin (BV) could normalize FDG PET in platinum-refractory HL prior to ASCT. Fifteen consecutive patients with RR HL and FDG PET positive disease after platinum-based salvage therapy were treated with a median of 4 cycles of BV. Normalization of FDG PET (Deauville ≤2) occurred in 8/15 (53%) patients but was only observed in patients that had achieved partial remission or stable disease after platinum-based salvage therapy. All patients eventually proceeded to ASCT, regardless of FDG PET status. Our data suggest that BV can normalize FDG PET in a subset of patients with platinum-refractory HL prior to ASCT.
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.
authors.forename: Maika
authors.initials: M
authors.lastname: Onishi
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Solomon A
authors.initials: SA
authors.lastname: Graf
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Leona
authors.initials: L
authors.lastname: Holmberg
authors.affiliation: Department of Radiology, University of Washington, Seattle, WA, USA.
authors.forename: Sanaz
authors.initials: S
authors.lastname: Behnia
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Andrei R
authors.initials: AR
authors.lastname: Shustov
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Karen
authors.initials: K
authors.lastname: Schiavo
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Mary
authors.initials: M
authors.lastname: Philip
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Edward N
authors.initials: EN
authors.lastname: Libby
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Ryan D
authors.initials: RD
authors.lastname: Cassaday
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: John M
authors.initials: JM
authors.lastname: Pagel
authors.affiliation: Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Roden
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: David G
authors.initials: DG
authors.lastname: Maloney
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Damian J
authors.initials: DJ
authors.lastname: Green
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Brian G
authors.initials: BG
authors.lastname: Till
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Oliver W
authors.initials: OW
authors.lastname: Press
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Smith
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.|Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Gopal
mesh_terms: D000293:Adolescent; D000328:Adult; D000079963:Brentuximab Vedotin; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010984:Platinum / Q000378:metabolism*; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018796:Immunoconjugates; D019788:Fluorodeoxyglucose F18; D010984:Platinum; D000079963:Brentuximab Vedotin
keywords: Hodgkin lymphoma; autologous transplant; brentuximab vedotin